Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Share-based Compensation (2016 - 2025)

Lexaria Bioscience's Share-based Compensation history spans 10 years, with the latest figure at $74895.0 for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 24.66% year-over-year to $74895.0; the TTM value through Nov 2025 reached $834974.0, up 55.29%, while the annual FY2025 figure was $859494.0, 74.61% up from the prior year.
  • Share-based Compensation for Q4 2025 was $74895.0 at Lexaria Bioscience, down from $122724.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $470136.0 in Q2 2025 and bottomed at -$66041.0 in Q2 2021.
  • The 5-year median for Share-based Compensation is $90755.0 (2021), against an average of $130582.8.
  • The largest YoY upside for Share-based Compensation was 10580.89% in 2021 against a maximum downside of 109.68% in 2021.
  • A 5-year view of Share-based Compensation shows it stood at $408544.0 in 2021, then plummeted by 83.17% to $68776.0 in 2022, then decreased by 21.55% to $53953.0 in 2023, then surged by 84.26% to $99415.0 in 2024, then decreased by 24.66% to $74895.0 in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Share-based Compensation are $74895.0 (Q4 2025), $122724.0 (Q3 2025), and $470136.0 (Q2 2025).